• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Reports First Quarter 2025 Financial Results

    5/13/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories 

    Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others

    Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States

    Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes

    MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the first quarter-ended March 31, 2025, and provided an update on recent business highlights.

    "Our first quarter results demonstrate the positive trends we expect to build on in 2025 as we secure new opportunities to drive volume across our VLN®, core CMO and filtered cigar businesses, with a particular emphasis on leveraging both our own and customer driven campaigns for partner branded products," said Larry Firestone, CEO of 22nd Century Group.

    "The investments we made in 2024 to transition to profitable CMO activity have begun to pay off as we secure new and increased volumes at existing, returning and new customers for 2025. Sales increased by approximately 50% from the fourth quarter and the operating leverage is flowing through our low-cost operating model."

    "We are excited about the upcoming launch of now two partner branded VLN® products, both for chains with substantial retail store counts, bringing additional partner supported marketing and outreach activity to grow sales volumes in the VLN® category. We are moving ahead on these and other opportunities ahead as we continue to execute our growth strategy in 2025."

    First Quarter 2025 Financial Results (compared to Fourth Quarter 2024, except as noted)

    All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company's hemp/cannabis business in late 2023.

    • Net revenues increased approximately 50% sequentially to $6.0 million, compared to $4.0 million.
    • Gross profit (loss) declined to $(0.6) million, compared to $(1.3) million.
    • Operating expenses decreased to $2.0 million, compared to $2.8 million, the lowest quarterly amount since the restructuring began in 2023.
    • Operating loss decreased to $2.6 million, compared to net loss of $4.1 million.
    • Net loss decreased to $3.3 million, compared to $4.2 million.
    • Adjusted EBITDA loss was $2.3 million, improved from a loss of $3.9 million.
    • Ended first quarter 2025 with net debt of $3.4 million.

    Recent Business Highlights

    • Implemented a new VLN® logo, packaging and marketing plan for relaunch of the Company's branded products.
    • Launched VLN® Red, joining VLN® Gold and Green, expanding the reduced nicotine content category for adult smokers.
    • Submitted regulatory filings in all 50 states for VLN®, partner VLN® brands and other products planned for 2025 launches.
    • Readying for shipments of the first VLN® partner brand products, now expected with two of 22nd Century's largest customers.
    • Advanced customer negotiations with new customers to expand VLN® distribution and launch additional VLN® partner brands, further diversifying the reduced nicotine content product category.
    • Began shipments of conventional products under a new five-year expanded license and manufacturing agreement with Smoker Friendly, covering 11 existing products plus eight new premium products.
    • Began shipments of Smoker Friendly Black Label branded tobacco and water natural style cigarettes
    • Secured two new long-term filtered cigar agreements with proven customers under newly priced contracts.
    • Reduced total operating expenses to the lowest level since the restructuring began in 2023.

    First Quarter 2025 Product Line Net Revenues

    • Cigarette net revenues were $5.0 million, increased from $3.3 million in the fourth quarter of 2024 reflecting additional volume from new customer contracts with largest CMO customer effective January 1, 2025, including the initial impact of accounting for revenue accruals recorded as over-time revenue recognition. Q1 2025 cigarette carton volumes increased to 319 thousand compared to 228 thousand in the fourth quarter of 2024.
    • Filtered cigar net revenues increased to $1.1 million, compared to $0.8 million in the immediately preceding quarter, reflecting additional volume from new contracts with CMO customers executed in March 2025.
    • Cigarillo distribution net revenues for both the first quarter 2025 and fourth quarter 2024 were negligible and reflect the time necessary for initial stocking orders in 2024 to be sold through our distributors before additional reorders are fulfilled in the second half of 2025.
    • VLN® cigarette net revenues reflect return accruals for product previously shipped. The Company has announced new branding for its VLN® products and its first partner brand VLN® products with large existing customers. Additional partner brand agreements are in progress as part of a relaunch of its VLN® reduced nicotine content products.

    Balance Sheet

    • The Company reported total debt of approximately $4.6 million at quarter end, and net debt of approximately $3.4 million.
    • Subsequent to the quarter end, the Company further reduced debt to approximately $3.9 million, and has now reduced debt by $3.7 million year-to-date while simultaneously funding its working capital needs for inventory and receivables.

    Conference Call

    22nd Century will host a live webcast today at 8:00 a.m. E.T. to discuss its first quarter 2025 financial results and business highlights. The live and archived webcast will be accessible in the Events section on 22nd Century's Investor Relations website at https://ir.xxiicentury.com/events.

    Summary Financial Results

    (dollars in thousands, except per share data)

      Three Months Ended
      March 31,  Change
      2025  2024  $%
    Revenues, net $5,956  $6,469  (513)(7.9)
    Gross profit (loss) $(609) $(1,129) 520 (46.1)
    Operating loss $(2,570) $(4,434) 1,864 (42.0)
    Net loss from continuing operations $(3,274) $(5,450) 2,176 (39.9)
    Basic and diluted loss per common share from continuing operations $(1.89) $(230.82) 229 (99.2)
    Adjusted EBITDA (a) $(2,319) $(3,500) 1,181 33.8 
              
    (a) Adjusted EBITDA is a non-GAAP financial measure. Please see "Notes Regarding Non-GAAP Financial Information" for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.
     

    Summary Product Line Results

    (in thousands)

      Three Months Ended
      March 31,    
      2025  2024 Change
      $Cartons $Cartons $Cartons
    Contract Manufacturing         
    Cigarettes 5,013 319  2,76091 2,253 228 
    Filtered Cigars 1,103 159  3,626536 (2,523)(377)
    Cigarillos (5)-  -- (5)- 
    Total Contract Manufacturing 6,111 478  6,386627 (275)(149)
    VLN® (155)(2) 831 (238)(3)
    Total Product Line Revenues 5,956 476  6,469628 (513)(152)
                  

    About 22nd Century Group, Inc.

    22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.

    We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.

    Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.

    Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets. Our mission is to sell the last cigarette before the 22nd Century.

    VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 20, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Notes regarding Non-GAAP Financial Information

    In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company provides EBITDA and Adjusted EBITDA.

    In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.

    The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.

    Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. In addition to the performance measures identified above, we believe that net total debt provides a meaningful measure of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of scheduled debt repayments.

    Investor Relations & Media Contact

    Matt Kreps

    Investor Relations

    22nd Century Group

    [email protected]

    214-597-8200

    22nd CENTURY GROUP, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

      March 31,  December 31, 
      2025  2024 
    ASSETS      
    Current assets:      
    Cash and cash equivalents $1,133  $4,422 
    Accounts receivable, net  4,322   1,698 
    Inventories  2,555   2,015 
    Insurance recoveries  768   768 
    GVB promissory note  —   500 
    Prepaid expenses and other current assets  1,559   1,068 
    Current assets of discontinued operations held for sale  758   1,051 
    Total current assets  11,095   11,522 
    Property, plant and equipment, net  2,662   2,773 
    Operating lease right-of-use assets, net  1,572   1,639 
    Intangible assets, net  6,114   5,724 
    Other assets  15   15 
    Total assets $21,458  $21,673 
           
    LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)      
    Current liabilities:      
    Notes and loans payable - current $—  $254 
    Current portion of long-term debt  3,929   1,500 
    Operating lease obligations  272   261 
    Accounts payable  3,089   2,401 
    Accrued expenses  2,121   1,021 
    Accrued litigation  768   768 
    Accrued payroll  208   318 
    Accrued excise taxes and fees  3,849   2,038 
    Deferred income  79   20 
    Other current liabilities  1,223   100 
    Current liabilities of discontinued operations held for sale  858   1,281 
    Total current liabilities  16,396   9,962 
    Long-term liabilities:      
    Operating lease obligations  1,363   1,437 
    Long-term debt  —   5,165 
    Other long-term liabilities  74   1,097 
    Total liabilities  17,833   17,661 
    Shareholders' equity (deficit)      
    Preferred stock, $.00001 par value, 10,000,000 shares authorized      
    Common stock, $.00001 par value, 250,000,000 shares authorized      
    Capital stock issued and outstanding:      
    2,733,232 common shares (730,148 at December 31, 2024)      
    Common stock, par value  —   — 
    Capital in excess of par value  401,824   397,883 
    Accumulated deficit  (398,199)  (393,871)
    Total shareholders' equity  3,625   4,012 
    Total liabilities and shareholders' equity $21,458  $21,673 



    22nd CENTURY GROUP, INC.


    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited)

    (amounts in thousands, except share and per-share data)

     Three Months Ended
     March 31, 
     2025  2024 
    Revenues, net$5,956  $6,469 
    Cost of goods sold 2,884   4,213 
    Excise taxes and fees on products 3,681   3,385 
    Gross (loss) profit (609)  (1,129)
    Operating expenses:     
    Sales, general and administrative 1,799   2,906 
    Research and development 162   425 
    Other operating expense, net —   (26)
    Total operating expenses 1,961   3,305 
    Operating loss from continuing operations (2,570)  (4,434)
    Other income (expense):     
    Other income (expense), net (162)  — 
    Interest income, net 16   — 
    Interest expense (558)  (1,016)
    Total other income (expense), net (704)  (1,016)
    Loss from continuing operations before income taxes (3,274)  (5,450)
    Provision for income taxes —   — 
    Net loss from continuing operations$(3,274) $(5,450)
          
    Discontinued operations:     
    Loss from discontinued operations before income taxes$(1,054) $(289)
    Provision for income taxes —   — 
    Loss from discontinued operations$(1,054) $(289)
          
    Net loss$(4,328) $(5,739)
    Comprehensive loss$(4,328) $(5,739)
          
    Net loss$(4,328) $(5,739)
    Deemed dividends —   (3,589)
    Net loss available to common shareholders$(4,328) $(9,328)
          
    Basic and diluted loss per common share from continuing operations$(1.89) $(230.82)
    Basic and diluted loss per common share from discontinued operations$(0.61) $(12.25)
    Basic and diluted loss per common share from deemed dividends$—  $(152.00)
    Basic and diluted loss per common share$(2.50) $(395.07)
          
    Weighted average shares outstanding - basic and diluted 1,729,212   23,612 
          

    Table A – Reconciliations of Non-GAAP Measures

    (dollars in thousands, except share and per-share data)

    Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the three month periods ended March 31, 2025 and 2024, including a reconciliation of these Non-GAAP measures for such periods.

      Quarter Ended
      March 31, 
      Amounts in thousands ($000's)
      except share and per share data
      (UNAUDITED)
             $ Change 
      2025  2024   fav / (unfav)1
    Net loss from continuing operations $ (3,274) $ (5,450) $ 2,175 
    Interest (income)/expense, net  543   1,016   (473)
    Provision (benefit) for income taxes  —   —   — 
    Amortization and depreciation  224   266   (42)
    EBITDA $ (2,507) $ (4,168) $ 1,661 
    Adjustments:         
    Restructuring and impairment  —   (26)  26 
    Inventory write-down  —   431   (431)
    Change in fair value of derivative liabilities  —   82   (82)
    Change in fair value of warrant liabilities  162   —   162 
    Equity-based employee compensation expense  26   181   (155)
    Adjusted EBITDA $ (2,319) $ (3,500) $ 1,181 
              
    Adjusted EBITDA loss per common share $(1.34) $(148.24) $146.90 
    Weighted average common shares outstanding - basic and diluted  1,729,212   23,612    
                

    1Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA

    Table B: Net Total Debt Reconciliation

    (dollars in thousands)

      March 31,  December 31, 
      2025 2024
    Total debt $3,929 $6,665
    Add: debt discounts and deferred issuance costs included in total debt  628  1,025
    Total principal amount of debt outstanding  4,558  7,690
    Less: Cash and cash equivalents  1,133  4,422
    Net total debt (Non-GAAP) $3,425 $3,268


    Primary Logo

    Get the next $XXII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:37:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salhany Lucille S was granted 2,472 shares, increasing direct ownership by 49,440% to 2,477 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:35:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Arno Andrew was granted 4,237 shares, increasing direct ownership by 9,015% to 4,284 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:30:19 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

      Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      7/21/22 9:12:19 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on 22nd Century Group with a new price target

      Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      6/15/22 7:42:24 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Roth Capital initiated coverage on 22nd Century Group with a new price target

      Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

      3/8/22 9:21:23 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 22nd Century Group Reports First Quarter 2025 Financial Results

      Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

      5/13/25 6:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      12/3/24 11:18:54 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      11/14/24 5:56:57 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by 22nd Century Group Inc.

      SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

      10/23/24 7:27:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Financials

    Live finance-specific insights

    See more
    • 22nd Century Group Reports First Quarter 2025 Financial Results

      Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

      5/13/25 6:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

      For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

      12/23/21 9:06:12 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    SEC Filings

    See more
    • SEC Form 10-Q filed by 22nd Century Group Inc.

      10-Q - 22nd Century Group, Inc. (0001347858) (Filer)

      5/13/25 6:30:33 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 22nd Century Group, Inc. (0001347858) (Filer)

      5/13/25 6:03:02 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-3 filed by 22nd Century Group Inc.

      S-3 - 22nd Century Group, Inc. (0001347858) (Filer)

      5/8/25 5:00:51 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      9/12/24 5:00:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      5/31/24 4:05:20 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      1/8/24 8:04:11 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    See more
    • 22nd Century Announces Resignation of John Miller as President of Tobacco

      Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

      5/30/24 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

      BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

      9/12/22 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

      CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea

      6/16/22 8:30:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care